Curaleaf Reports Second Quarter 2026 Results: Continued Growth, Margin Strength, and Profitability
Curaleaf Holdings reported Q2 2026 net revenue of $340.1 million, up 10% year over year, with gross margin at 50% and net income from continuing operations of $12.5 million. Adjusted EBITDA was $70.1 million. International revenue was $51 million. The company ended the quarter with $107.0 million cash and said it expanded retail and completed its Four20 Pharma buyout.
How this was made
The 30-second read
Why it matters
The release combines financial performance (revenue, margins, net income, adjusted EBITDA) with operational catalysts (Florida dispensary openings, Dark Heart launch, Four20 Pharma ownership to 100%, DEA registration application).
Market read
This is a primary earnings release with quantified profitability and growth metrics, plus operational updates that can affect near-term sentiment and forward expectations.
What to watch
The text highlights cash ($107M) and debt ($611.5M) but does not discuss free cash flow or leverage trajectory, which could dominate valuation reactions.
Background
Curaleaf is reporting Q2 2026 results and operational updates, including retail footprint expansion, a brand launch, and completing a buyout of its German subsidiary.
Ticker impact
Curaleaf reported Q2 2026 net revenue of $340.1M (+10% YoY), gross margin of 50%, and adjusted EBITDA of $70.1M.
Near-term trading likely hinges on whether investors focus on top-line growth and gross margin versus the EBITDA margin decline.
The article provides multiple quantified KPIs (revenue, gross margin, net income, adjusted EBITDA and margin) but no guidance or consensus comparison, limiting conviction on direction.
Market effects
Cannabis operators may see read-across interest from Curaleaf’s reported margin strength and international growth, but EBITDA margin compression tempers the signal.
US-focused momentum narrative (domestic YoY growth) could influence sentiment toward US cannabis retail operators.
International segment growth (26% YoY) supports the broader theme of scaling non-US operations, though details are limited.
Counterpoint
Investors may discount the headline gross margin strength if adjusted EBITDA margin continued to deteriorate, suggesting underlying operating leverage is not improving.
Key entities
- companyCuraleaf Holdings, Inc.
Reported Q2 2026 net revenue of $340.1M, gross margin of 50%, adjusted EBITDA of $70.1M, and cash of $107.0M.
- subsidiaryFour20 Pharma
Curaleaf completed the buyout of the remaining 45% equity interest, increasing Curaleaf International ownership to 100%.
- regulatorDEA
Curaleaf applied to register all medical cultivation, processing, and dispensing locations.
